Kirk is the CEO of Quantify Research and serves on its Board of Directors. He is currently a PhD candidate at the Department of Public Health and Clinical Medicine at Umeå University (Sweden), where he studies psoriasis patients’ clinical and economic outcomes using observational registry data. He holds a MSc from Lund University (Sweden) in Economics, specializing in econometrics. He also holds a Bachelor of Commerce in Management Economics in Industry and Finance from the Gordon S. Lang School of Business and Economics at Guelph University (Canada).

He has 10 years’ of international work experience in health economics and outcomes research (HEOR) at Quantify Research, Parexel International, and in academia. Kirk has hands-on experience in a variety of areas including real-world evidence generation, economic modelling, value demonstration in health technology assessment and evidence synthesis. Kirk is active in the research community and regularly lectures at industry and academic conferences. His disease area expertise spans dermatology, respiratory, immunology, women’s health, central nervous system, and musculoskeletal.

Dr Fredrik Borgström, MSc, PhD, is one of the co-founders of Quantify and currently chairman of the board. He has over 20 years’ experience in providing consultancy services to industry, private and public organizations and institutions within the field of health economics and outcomes research, real world evidence and market access.

Previous to starting Quantify, he was managing the Swedish operations Fredrik at i3 Innovus. where he managed the Swedish operations. Fredrik has been involved in projects in several disease areas, including osteoporosis, rheumatoid arthritis, osteoarthritis, oncology, multiple sclerosis, menopausal symptoms and cardiovascular disease.

Fredrik has been author of more than 100 articles published in scientific journals. His research covers methods such as modeling, data collection and statistical analysis of retrospective and prospective data.

Dr. Oskar Ström is one of Quantify’s co-founders and sits on the board of directors. He is a registered pharmacist with a Master’s degree in pharmaceutical bioscience from Uppsala University and has a PhD in pharmacoepidemiology from Karolinska Institutet, Sweden. Oskar has extensive experience in health economics, and retrospective and prospective study design and analysis.

Oskar has 17 years’ experience as a consultant to industry, private and public organizations and institutions in the field of health economics and outcomes research. He has worked in a wide range of areas, including osteoporosis, hip arthroplasty, rheumatoid arthritis, postmenopausal symptoms, glaucoma, migraine, asthma, liver disease, spine surgery, and treatment adherence and provision. He has been lead author and co-author of over 50 peer-reviewed manuscripts and has presented at several scientific conferences.

Oskar is an affiliated researcher at the departement of medicine at Karolinska Institutet, focusing on retrospective research in Chronic Liver Disease.

Dr Anders Gustavsson holds an MSc from the Stockholm School of Economics and a PhD in Health Economics from Karolinska Institutet, Sweden.

During his PhD studies, Anders developed new methods for the economic evaluation of treatment for Alzheimer’s disease. Anders has worked with health economics since 2005, first as researcher at European Health Economics and from 2008 as Associate Director at i3 Innovus, leading a research team in neuroscience. As a consultant, Anders has worked with pharma and biotech companies, patient organisations, health care providers and government institutions.

He has a broad competence within research and has co-authored about 30 peer-reviewed papers including registry studies, prospective cohorts, within-trial analysis, patient- and caregiver preference studies and decision analytic models. Anders was coordinator and first author of the European study on the costs of brain disorders (2010), initiated by European Brain Council.

He is affiliated to Karolinska Institutet and a co-organiser of the International Pharmaco-Economic Conference on Alzheimer’s disease (IPECAD).

Dr Johan Mesterton holds a Master’s degree in Economics from Uppsala University and a PhD in Health Care Management from Karolinska Institutet, Sweden.

Prior to co-founding Quantify Research, Johan led a team focused on analysis of retrospective data at i3 Innovus. Johan has more than 15 years’ experience of analysis of health care data, with a specific focus on biostatistics and analysis of real-world register data. He has worked on behalf of both pharmaceutical and biotech companies, payer and provider organizations, as well as patient organizations.

His PhD studies focused on the merits and challenges associated with continuous comparisons of health care outcomes and costs between different payers and providers. Johan’s research has covered a wide range of different therapeutic areas and methodologies, and has included data from numerous different health care systems.

Mary is the director of Quantify Research Denmark. She holds master’s degree in Public Health from the University of Copenhagen and has more than 18 years of experience in Real-world evidence and Market access, both from working with data, project management, and as a leader. Prior to joining Quantify Research, Mary worked for different Danish authorities like the Danish Health Data Authority and the Danish Medicine Agency, as well as in health economics consultancy.

Almost two decades of experience from within the healthcare system has given Mary a broad network among academia and health care professionals in Denmark. She has been supporting clients from both the public sector and pharmaceutical companies to reach their targets and create a more value-based healthcare, on a national and Nordic level. She has long experience from both strategical work and method development within Real-world evidence.

Mary has experience from a multitude of different therapeutic areas, including for example psychiatric disorders, diabetes, respiratory diseases, and infectious diseases.

Puneet serves as the country director for Quantify HEOR Private Limited and serves on its Board of Directors along with Johan Mesterton and Kirk Geale. He holds a Masters in Pharmaceutical Sciences with a specialization in Drug Regulatory Affairs from MD University, Rohtak, India. He also holds a professional diploma in clinical research and also a certification in Health economics from Indian Institute of Public Health. Puneet has undergone various leadership trainings and certifications during his leadership roles at Eli Lilly and BresMed.

He has 11 years’ of global work experience in health economics and outcomes research (HEOR) at WNS global services, Parexel, Eli Lilly, BresMed and Quantify Research. Puneet has hands-on experience in a variety of areas including evidence synthesis (systematic, targeted and focused literature reviews), real-world evidence generation, developing inputs to economic models, value demonstration in health technology assessment and authoring manuscripts in leading medical journals. Puneet has significant experience in developing high performance teams with quality delivery mindset and loves to mentor and coach upcoming leaders. His disease area expertise spans oncology, diabetes, dermatology, respiratory, immunology, musculoskeletal, and metabolic disorders.